The National Institute for Health and Care Excellence (NICE) has issued a final appraisal decision (FAD) recommending the reimbursement of lenvatinib (Lenvima) for the treatment of differentiated thyroid cancer.
Original Article: NICE recommends reimbursement of lenvatinib for thyroid cancer